HMGN (Hemagen Diagnostics) Current Deferred Revenue: $0.02 Mil (As of Sep. 2012)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Hemagen Diagnostics Current Deferred Revenue?

Hemagen Diagnostics HMGN Current Deferred Revenue is $0.02 Mil as of Sep. 2012.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Hemagen Diagnostics's current deferred revenue for the quarter that ended in Sep. 2012 was $0.02 Mil.

Hemagen Diagnostics Current Deferred Revenue Related Terms

Hemagen Diagnostics Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Hemagen Diagnostics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemagen Diagnostics Current Deferred Revenue Chart

Hemagen Diagnostics Annual Data
Trend Sep03 Sep04 Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.05 0.03 0.04 0.02

Hemagen Diagnostics Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.03 0.04 0.03 0.02
What does a Current Deferred Revenue of $0.02 Mil mean?
Hemagen Diagnostics (HMGN) has a Current Deferred Revenue of $0.02 Mil as of Sep. 2012. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Hemagen Diagnostics and its competitors.
Is Hemagen Diagnostics' Current Deferred Revenue too high?
Hemagen Diagnostics' current Current Deferred Revenue is $0.02 Mil.
How does Hemagen Diagnostics' Current Deferred Revenue compare to OBMP and NSPX?
Hemagen Diagnostics' Current Deferred Revenue of $0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Hemagen Diagnostics and its competitors. Hemagen Diagnostics's current Current Deferred Revenue is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemagen Diagnostics stock overvalued right now?
Hemagen Diagnostics (HMGN) has a current Current Deferred Revenue of $0.02 Mil. The current Current Deferred Revenue is $0.02 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Hemagen Diagnostics (HMGN), the current Current Deferred Revenue is $0.02 Mil as of Sep. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemagen Diagnostics Business Description

Address 9033 Red Branch Road, Columbia, MD, USA, 21045
Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.